Two staff investigators are proposed. Each has a distinct function and role coordinating unique activities that are not covered by other leadership positions in the Case CCC nor otherwise supported by the CCSG. Jill Barnholtz-Sloan, PhD, an expert in biostatistics and bioinformatics with a special interest in cancer genomics with links to clinical annotation, is spearheading the integration of annotated data sets across the Cancer Center and its consortium sites. She has a unique skill set in overcoming institutional barriers to collaborative efforts especially as it relates to clinical informatics for research. Her role as staff investigator will be to promote such activities across scientific programs, clinical research activities and sites, and to facilitate enhanced collaborative investigations. Yogen Saunthararajah, MD has developed strong collaborative efforts in the areas of drug discovery and drug development through his interest in targeted therapeutics. He is a member of the Hematopoietic Disorders and Developmental Therapeutics Programs where he has successfully developed new drugs that target myeloid malignancy differentiation through demethylation. In his role as staff investigator, he will further coordinate drug discovery and development of investigators across scientific programs and provide the interface from the basic laboratories to clinical investigation. In so doing, he will facilitate multiinvestigator interactions and grant applications. He will partner with Afshin Dowlati, MD, Director of the Center for Cancer Drug Development at CWRU, to provide closer interface with Cleveland Clinic colleagues and scientists.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464|
|Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726|
|He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135|
|Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:|
|Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173|
|Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414|
|Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143|
|Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279|
|Benson, Bryan L; Li, Lucy; Myers, Jay T et al. (2018) Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Sci Rep 8:9328|
|Bosca, Federica; Bielecki, Peter A; Exner, Agata A et al. (2018) Porphyrin-Loaded Pluronic Nanobubbles: A New US-Activated Agent for Future Theranostic Applications. Bioconjug Chem 29:234-240|
Showing the most recent 10 out of 1227 publications